Cargando…

Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line.

Detalles Bibliográficos
Autores principales:	Citro, G., Cucco, C., Verdina, A., Zupi, G.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1991
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977636/ https://www.ncbi.nlm.nih.gov/pubmed/1911196

Ejemplares similares

Phase II study of lonidamine in metastatic breast cancer.
por: Pronzato, P., et al.
Publicado: (1989)

Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo.
por: Del Bufalo, D., et al.
Publicado: (1996)

Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line
por: Li, Jie, et al.
Publicado: (2001)

Discovering a Reversible Male Contraceptive Agent Derived from Lonidamine
por: Gong, Shengnan, et al.
Publicado: (2023)

Germacrone reverses Adriamycin resistance through cell apoptosis in multidrug-resistant breast cancer cells
por: XIE, XIAO-HONG, et al.
Publicado: (2014)

Ophiobolin-O Reverses Adriamycin Resistance via Cell Cycle Arrest and Apoptosis Sensitization in Adriamycin-Resistant Human Breast Carcinoma (MCF-7/ADR) Cells
por: Sun, Wenxia, et al.
Publicado: (2013)

Characterisation of adriamycin- and amsacrine-resistant human leukaemic T cell lines.
por: Snow, K., et al.
Publicado: (1991)

Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin.
por: Nishio, K., et al.
Publicado: (1990)

Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells.
por: Twentyman, P. R., et al.
Publicado: (1986)

A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
por: Mansi, J. L., et al.
Publicado: (1991)

NMR spectroscopy analysis of phosphorus metabolites and the effect of adriamycin on these metabolite levels in an adriamycin-sensitive and -resistant human small cell lung carcinoma cell line.
por: de Jong, S., et al.
Publicado: (1991)

Effects of the Combination of Gliotoxin and Adriamycin on the Adriamycin-Resistant Non-Small-Cell Lung Cancer A549 Cell Line
por: Manh Hung, Le Van, et al.
Publicado: (2018)

Inhibition of the recovery from potentially lethal damage by lonidamine.
por: Hahn, G. M., et al.
Publicado: (1984)

Ru(III) Complexes with Lonidamine-Modified Ligands
por: Shutkov, Ilya A., et al.
Publicado: (2021)

Phase II study of lonidamine in non-small cell lung cancer: final report.
por: Kokron, O., et al.
Publicado: (1990)

Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems.
por: Silvestrini, B., et al.
Publicado: (1983)

The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment
por: Huang, Yaxin, et al.
Publicado: (2020)

Effect of lonidamine derivatives on the inhibition of transformed cell area expansion
por: Aoyama, Megumi, et al.
Publicado: (2023)

Re-programming tumour cell metabolism to treat cancer: no lone target for lonidamine
por: Bhutia, Yangzom D., et al.
Publicado: (2016)

Glutathione Programmed Mitochondria Targeted Delivery of Lonidamine for Effective Against Triple Negative Breast Cancer
por: Wang, Zhongjie, et al.
Publicado: (2023)

Inhibition of Mitochondrial Complex II by the Anticancer Agent Lonidamine
por: Guo, Lili, et al.
Publicado: (2016)

Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells
por: Cao, Bei, et al.
Publicado: (2013)

Adriamycin-resistant cells are significantly less fit than adriamycin-sensitive cells in cervical cancer
por: Qi, Min, et al.
Publicado: (2021)

Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis
por: Cheng, Gang, et al.
Publicado: (2019)

Chemosensitization to adriamycin by cyclosporin A and verapamil in human retinoblastoma cell lines.
por: Lee, T. W., et al.
Publicado: (1993)

Directly targeting ASC by lonidamine alleviates inflammasome-driven diseases
por: Chen, Chen, et al.
Publicado: (2022)

Flow Cytometric Analysis of Early Steps in Development of Adriamycin Resistance in a Human Gastric Cancer Cell Line
por: Tanaka, Shinsuke, et al.
Publicado: (1994)

Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells.
por: Citro, G., et al.
Publicado: (1994)

Stimulation of the apoptotic response as a basis for the therapeutic synergism of lonidamine and cisplatin in combination in human tumour xenografts.
por: De Cesare, M., et al.
Publicado: (1998)

Therapeutic Efficacy and Safety of Paclitaxel/Lonidamine Loaded EGFR-Targeted Nanoparticles for the Treatment of Multi-Drug Resistant Cancer
por: Milane, Lara, et al.
Publicado: (2011)

Reversal of Tumor Necrosis Factor Resistance in Tumor Cells by Adriamycin via Suppression of Intracellular Resistance Factors
por: Watanabe, Naoki, et al.
Publicado: (1995)

Amplification of anticancer efficacy by co-delivery of doxorubicin and lonidamine with extracellular vesicles
por: Li, Huizhen, et al.
Publicado: (2022)

New Organometallic Ru(II) Compounds with Lonidamine Motif as Antitumor Agents
por: Shutkov, Ilya A., et al.
Publicado: (2023)

WYE-354 restores Adriamycin sensitivity in multidrug-resistant acute myeloid leukemia cell lines
por: Ibrahim, Sara M., et al.
Publicado: (2019)

Identification of proteins responsible for adriamycin resistance in breast cancer cells using proteomics analysis
por: Wang, Zhipeng, et al.
Publicado: (2015)

Acute Induction of Adriamycin‐resistance in Human Colon Carcinoma HT‐29 Cells Exposed to a Sublethal Dose of Adriamycin
por: Tomida, Akihiro, et al.
Publicado: (1995)

Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line.
por: Twentyman, P. R., et al.
Publicado: (1987)

Mitochondrial Targeting and pH-Responsive Nanogels for Co-Delivery of Lonidamine and Paclitaxel to Conquer Drug Resistance
por: Chen, Enping, et al.
Publicado: (2021)

Compound 968 reverses adriamycin resistance in breast cancer MCF-7(ADR) cells via inhibiting P-glycoprotein function independently of glutaminase
por: Yang, Ronghui, et al.
Publicado: (2021)

Attenuation of neuroinflammation reverses Adriamycin-induced cognitive impairments
por: Allen, Barrett D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hqihriq6bau18ospeoci321v9d